Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
© 2024. The Author(s)..
BACKGROUND: Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself.
METHODS: The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage of unmutated BCRs in the repertoire. The predictive value of early BCR-depletion (within one-month post-treatment) and early BCR-repopulation (within 6 months post-treatment) on clinical response was assessed.
RESULTS: We observed changes in the peripheral blood BCR repertoire after rituximab treatment, i.e., increased clonal expansion, decreased clonal diversification and increased mutation load which persisted up to 12 months after treatment, but started to revert at month 6. Early BCR depletion was not associated with early clinical response but late depleters did show early response. Patients with early repopulation with unmutated BCRs showed a significant decrease in disease activity in the interval 6 to 12 months. Development of anti-drug antibodies non-significantly correlated with more BCR repopulation.
CONCLUSION: Our findings indicate that rather than BCR-depletion it is repopulation with unmutated BCRs, possibly from naïve B cells, which induces remission. This suggests that (pre-existing) differences in B-cell turnover between patients explain the interindividual differences in early clinical effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Arthritis research & therapy - 26(2024), 1 vom: 16. März, Seite 70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pollastro, Sabrina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 19.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13075-024-03297-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369828860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369828860 | ||
| 003 | DE-627 | ||
| 005 | 20240319233058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-024-03297-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369828860 | ||
| 035 | |a (NLM)38493208 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pollastro, Sabrina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself | ||
| 520 | |a METHODS: The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage of unmutated BCRs in the repertoire. The predictive value of early BCR-depletion (within one-month post-treatment) and early BCR-repopulation (within 6 months post-treatment) on clinical response was assessed | ||
| 520 | |a RESULTS: We observed changes in the peripheral blood BCR repertoire after rituximab treatment, i.e., increased clonal expansion, decreased clonal diversification and increased mutation load which persisted up to 12 months after treatment, but started to revert at month 6. Early BCR depletion was not associated with early clinical response but late depleters did show early response. Patients with early repopulation with unmutated BCRs showed a significant decrease in disease activity in the interval 6 to 12 months. Development of anti-drug antibodies non-significantly correlated with more BCR repopulation | ||
| 520 | |a CONCLUSION: Our findings indicate that rather than BCR-depletion it is repopulation with unmutated BCRs, possibly from naïve B cells, which induces remission. This suggests that (pre-existing) differences in B-cell turnover between patients explain the interindividual differences in early clinical effect | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIRR-seq | |
| 650 | 4 | |a B cells | |
| 650 | 4 | |a B-cell receptor repertoire | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Rituximab | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, B-Cell |2 NLM | |
| 700 | 1 | |a Musters, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Balzaretti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Niewold, Ilse |e verfasserin |4 aut | |
| 700 | 1 | |a van Schaik, Barbera |e verfasserin |4 aut | |
| 700 | 1 | |a Hässler, Signe |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoef, Catharina M |e verfasserin |4 aut | |
| 700 | 1 | |a Pallardy, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a van Kampen, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Mariette, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Niek |e verfasserin |4 aut | |
| 700 | 0 | |a ABIRISK Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Szely, Natacha |e investigator |4 oth | |
| 700 | 1 | |a Gleizes, Aude |e investigator |4 oth | |
| 700 | 1 | |a Abina, Salima Hacein-Bey |e investigator |4 oth | |
| 700 | 1 | |a Richez, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Soubrier, Martin |e investigator |4 oth | |
| 700 | 1 | |a Avouac, Jérome |e investigator |4 oth | |
| 700 | 1 | |a Brocq, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Sellam, Jérémie |e investigator |4 oth | |
| 700 | 1 | |a Huizinga, Tom |e investigator |4 oth | |
| 700 | 1 | |a Jury, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Manson, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Mauri, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Matucci, Andrea |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 26(2024), 1 vom: 16. März, Seite 70 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:1 |g day:16 |g month:03 |g pages:70 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-024-03297-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 1 |b 16 |c 03 |h 70 | ||